Expression of cystatin M in breast cancer and metastatic cancer and its clinical significance

doi:10.3877/cma.j.issn.1674-0807.2008.03.007

Abstract

Abstract:

Objective

To explore the expression of cystatin M in breast cancer and its clinical significance.

Methods

RT-PCR was used to measure the level of cystatin M mRNA in 108 samples of breast cancer,30 samples of metastatic cancer and 24 samples of normal breast tissues. The relationship between the expression of cystatin M gene in human breast cancer and clinilcopathological features was analyzed.

Results

The cystatin M expression level of breast cancer samples was high in stage I/II breast cancer patients, but low in stage III/IV breast cancer patients,and there was a statistical significance between them. The systatin expression was high in ＜5 cm tumors, but low in ＞5 cm tumors, with a statistical significance between them.Cystatin M expression levels of breast cancer were correlated with TNM staging and clinical size of tumor. The expression levels of cystatin M in the breast cancer tissue were not significantly different from normal breast tissues and metastatic cancer tissues. Cystatin M expression levels of breast cancer were not correlated with lymph node metastasis, axillary lymph node status, histological grade or pathological type. Cystatin M expression levels of breast cancer and metastatic cancer were not correlated with HER-2, ER or PR status.

Conclusion

It needs to be discussed whether cystatin M can be a prognostic marker for breast cancer metastasis.

Key words: Breast neoplasms, Cystatin M, mRNA expression, Metastasis

Xin WANG, Zhe YAN, Xiao-qing LI, Yu-mei FENG, Xu-chen CAO. Expression of cystatin M in breast cancer and metastatic cancer and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(03): 21-25.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2008.03.007

https://zhrxbzz.cma-cmc.com.cn/EN/Y2008/V02/I03/21

Figures/Tables 1

References 12

[1]	柴凡,姜军,范林军. 乳腺癌预后相关分子标记物的研究进展. 中华乳腺病杂志(电子版),2007,1:56 -57.
[2]	Jedeszko C, Sloane B F. Cysteine cathepsins in human cancer.Biol Chem,2004,385:1017 -1027.
[3]	Ni J, Abrahamson M, Zhang M, et al. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem,1997,272:10 853 -10 858.
[4]	Sotiropoulou G,Anisowicz A,Sager R. Identification, cloning,and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem,1997,272:903 -910.
[5]	Zhang J, Shridhar R, Dai Q, et al. Cystatin M: a novel candidate tumor suppressor gene for breast cancer. Cancer Res,2004,64:6957 -6964.
[6]	Zeeuwen P L, van Vlijmen Willems I M, Egami H, et al.Cystatin M / E expression in inflammatory and neoplastic skin disorders. Br J Dermatol,2002,147:87 -94.
[7]	Vigneswaran N, Wu J, Muller S, et al. Expression analysis of cystatin C and M in laser-capture microdissectioned human breast cancer cells-a preliminary study. Pathol Res Pract,2005,200:753 -762.
[8]	Li X, Cao X, Li X, et al. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci,2007,98:1592 -1596.
[9]	万榕, 肖志芸, 王海燕, 等. 乳腺癌组织cystatin M 基因的表达及其临床病理意义. 癌变畸变突变, 2006,18:54 -57.
[10]	Nishikawa H, Ozaki Y, Nakanishi T, et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol,2004,92:881 -886.
[11]	Shridhar R, Zhang J, Song J, et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene,2004,23:2206-2215.
[12]	Vigneswaran N, Wu J, Sacks P, et al. Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. J Oral Pathol Med,2005,34:77 -86.

临床病理因数	例数	cystatin M平均秩次	P值
临床分期
I+II	82	58.18	0.030
III+IV	26	42.90	0.030
肿瘤直径
≤5cm	93	57.14	0.029
＞5cm	15	38.13	0.029
病理学类型
浸润性非特殊型癌	104	54.92	0.474
浸润性特殊型癌	4	43.50	0.474
组织学
Ⅰ	12	45.04	0.538
II	73	55.50
III	23	56.26
淋巴结转移数
0	52	54.31	0.914
1-3	22	57.57
4-9	15	50.03
≥10	19	55.00
乳腺癌ER状态
(+)	67	51.16	0.543
(-)	37	54.92	0.543
转移癌ER状态
(+)	15	15.40	0.534
(-)	13	13.46	0.534
乳腺癌PR状态
(+)	47	54.62	0.516
(-)	57	50.75	0.516
转移癌PR状态
(+)	6	14.83	0.911
(-)	22	14.48	0.911
乳腺癌HER-2状态
(+)	33	51.09	0.348
(-)	61	45.56	0.348
转移癌HER-2状态
(+)	12	13.50	1.000
(-)	14	13.50	1.000

临床病理因数	例数	cystatin M平均秩次	P值
临床分期
I+II	82	58.18	0.030
III+IV	26	42.90	0.030
肿瘤直径
≤5cm	93	57.14	0.029
＞5cm	15	38.13	0.029
病理学类型
浸润性非特殊型癌	104	54.92	0.474
浸润性特殊型癌	4	43.50	0.474
组织学
Ⅰ	12	45.04	0.538
II	73	55.50
III	23	56.26
淋巴结转移数
0	52	54.31	0.914
1-3	22	57.57
4-9	15	50.03
≥10	19	55.00
乳腺癌ER状态
(+)	67	51.16	0.543
(-)	37	54.92	0.543
转移癌ER状态
(+)	15	15.40	0.534
(-)	13	13.46	0.534
乳腺癌PR状态
(+)	47	54.62	0.516
(-)	57	50.75	0.516
转移癌PR状态
(+)	6	14.83	0.911
(-)	22	14.48	0.911
乳腺癌HER-2状态
(+)	33	51.09	0.348
(-)	61	45.56	0.348
转移癌HER-2状态
(+)	12	13.50	1.000
(-)	14	13.50	1.000

[1]	Yang Li, Jinyu Cai, Xiaozhi Dang, Wanying Chang, Yan Ju, Yi Gao, Hongping Song. Application value of a deep learning-based model for generating strain elastography images using breast grayscale ultrasound images [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 563-570.
[2]	Collaboration Group，Breast Cancer Specialty Committee，Hebei Anti-Cancer Association Nursing. Expert consensus on nursing management of central venous access in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 321-329.
[3]	Chenlu Liu, Jie Liu, Fan Zhang, Caiying Yan, Qian Chen, Shuangqing Chen. Habitat analysis based on enhanced MRI radiomic features in predicting HER-2 expression in breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 339-345.
[4]	Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[5]	Lin Qiu, Jinhui Liu, Tuerhong Zumureti, Yuexin Ma, Xiaoling Leng. Diagnostic value of ultrasound radiomics in non-mass breast cancer in dense breasts [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 353-360.
[6]	Shizhen Zhou, Xingya Zhu, Qinggang Yuan, Lixiang Liu, Kai Wang, Ji Miao, Chao Ding, Hao Wang, Wenxian Guan. Effect analysis of indocyanine green fluorescence imaging technique in laparoscopic lateral lymph node dissection of rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 44-47.
[7]	Jiehong Gao, Pingping Li, Jing Qi, Yinhai Dai. Study on the relationship between the expression of ETFA gene and clinicopathological parameters and prognosis in breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 64-67.
[8]	Mengmeng Han, Xueyuan Feng, Ning Ma. A case of radial nerve injury after modified radical surgery for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 117-118.
[9]	Bin He, Jinfeng Ma. Risk factors for splenic hilar lymph node metastasis in gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 694-699.
[10]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[11]	Lingyan Wang, Chunhui Gao, Xueyuan Feng, Xinmiao Cui, Huan Liu, Wenming Zhao, Jinku Zhang. Application of circulating tumor cells in neoadjuvant and postoperative adjuvant therapy for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 630-633.
[12]	Yi Lin, Wenlong Zhong, Kaiwen Li, Wang He, Tianxin Lin. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 15）: comprehensive treatment of metastatic bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 648-652.
[13]	Jingming Lu, Dawei Han, Yaoxing Ren, Tianxiao Huang, Junxi Xiang, Xufeng Zhang, Yi Lyu, Fumin Wang. Meta-analysis of lymph node metastasis prediction of intrahepatic cholangiocarcinoma based on preoperative radiomics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 852-858.
[14]	Runjin Zhang, Pan Yang, Yansi Lin, Zunlong Liu, Jianping Liu, Xiaoyan Jin. Epstein-Barr virus-associated cholangiocarcinoma complicated with multiple metastases: a case report and Chinese literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 865-869.
[15]	Yu Liu, Shaobin Duan, Zhixiang Ding, Zhitao Shi. Expression of miR-34a-5p in colon cancer patients and its correlation with clinical characteristics and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 485-490.

Please choose a citation manager

Content to export